Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer.
Conteduca V, Castro E, Wetterskog D, Scarpi E, Jayaram A, Romero-Laorden N, Olmos D, Gurioli G, Lolli C, Sáez MI, Puente J, Schepisi G, Salvi S, Wingate A, Medina A, Querol-Niñerola R, Marin-Aguilera M, Arranz JA, Fornarini G, Basso U, Mellado B, Gonzalez-Billalabeitia E, Attard G, De Giorgi U.
Conteduca V, et al. Among authors: scarpi e.
Eur J Cancer. 2019 Jul;116:158-168. doi: 10.1016/j.ejca.2019.05.007. Epub 2019 Jun 11.
Eur J Cancer. 2019.
PMID: 31200322